High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study
Martha Skinner(Boston University), Daniel G. Wright(University of Washington), John L. Berk(Boston University), Niall Swan(Boston University), Caryn Libbey, David C. Seldin(Boston University), Janice F. Wiesman(Boston University), Vaishali Sanchorawala(Boston Medical Center), Rodney H. Falk(Brigham and Women's Hospital), Kathleen T. Finn(Boston University), Jennifer J. Anderson(University of Calgary), Carl O’Hara(Deaconess Hospital), Laura M. Dember(Boston University), Karen Quillen(Boston University)
Cited by 615
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k